NCT01483781View on ClinicalTrials.gov

A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Diabetes Mellitus, Type 2Plasma Volume
Interventions
DRUG

Canagliflozin

Type = exact number, unit = mg, number = 300, form = capsule, route = oral use. One encapsulated tablet once daily for up to approximately 85 days (approximately 12 weeks)

DRUG

Placebo

Form = capsules, route = oral use. One capsule once daily for up to approximately 85 days (approximately 12 weeks)

Trial Locations (1)

Unknown

Neuss

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01483781 - A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter